© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Experts discuss existing treatment options for relapsed/refractory multiple myeloma and provide considerations for regimen selection and emerging treatment options.
April 15th 2021, 3:45pm
The in vitro study of melanoma cells analyzed the molecular mechanisms of the pair of proteasome inhibitors, finding that they reduced B16-F1 tumor growth.
April 13th 2021, 3:18pm
After cases of rare and severe blood clots led to 1 death and 1 hospitalization, the CDC and FDA will pause the use of Johnson & Johnson's (J&J) COVID-19 vaccine.
April 9th 2021, 11:45am
Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls.
April 4th 2021, 12:45pm
The combination of lenalidomide with steroid dexamethasone is standard of care in multiple myeloma (MM), but new research shows older patients can be spared the steroids.
April 3rd 2021, 9:30am
Multiple myeloma is the second most common blood cancer, affecting more than 130,000 US patients.
April 1st 2021, 12:40pm
Disease severity was strongly associated with health-related quality of life, moderately associated with use of disability insurance, and weakly associated with household income for patients with sickle cell disease.
March 25th 2021, 1:30pm
Twice weekly high doses of carfilzomib in combination with lenalidomide and dexamethasone was tolerable and effective among patients with newly diagnosed multiple myeloma.
March 24th 2021, 5:45pm
Updates to the NCCN Guidelines in multiple myeloma reflect recent trial results, giving clinicians and patients many choices.
March 18th 2021, 7:30pm
Minimal residual disease (MRD) is being used more frequently in clinical trials and to identify the best treatment course for patients, but unknowns remain about the optimal use of MRD testing.
March 16th 2021, 5:37pm
The safety and effectiveness of the long-acting agent is backed by data from trials of the drug among treatment-experienced individuals living with HIV-1 whose viral load is on the rise due to other regimens failing. Investigation continues among these patients, as well as treatment-naive patients.